Home›Advanced prostate cancer

Advanced prostate cancer: what it means and what can be done

It is worth being clear from the outset: once the disease has spread beyond the prostate, in most cases the goal of treatment is no longer cure. But not curable does not mean not treatable. With proper management, the disease is controlled, progression is delayed and life is extended — today, often for years, and with good quality.

"Advanced" is not one single thing

It is a word that covers very different situations, and confusing them causes unnecessary distress. It is worth knowing which one applies to you:

  • Locally advanced. The tumour has gone beyond the limits of the prostate but has not spread to distant sites. Here treatment with curative intent can be considered, generally combining several modalities.
  • With affected lymph nodes. An intermediate situation; treatment is more intensive and combined, and the outlook varies with the extent of involvement.
  • Metastatic. There are distant lesions, most often in bone. This is the setting in which the goal becomes long-term control of the disease.

That is why the most useful first question is not "how long do I have?" but "which of these situations am I in, exactly?". The answer changes the plan completely.

The essential point

A disease that cannot be cured can still be controlled for a long time. In advanced prostate cancer that difference is enormous: it is now managed as a chronic condition requiring follow-up and adjustment, not as an inevitable short-term outcome.

Dr. Eduardo Amaya Fragoso

Written and reviewed by

Dr. Eduardo Amaya Fragoso

Urologic Surgeon · Fellowship in Urologic Oncology (Centro Médico Nacional Siglo XXI · UNAM) · International Fellow in Robotic Urology (Instituto Israelita Albert Einstein, Brazil)

Professional Licence 10407470 · Specialty Licence 12943253 · CONAMEU 1918 (valid 2022–2027). Practice at Hospital San José, Hermosillo, Sonora.

Last reviewed: 23 July 2026

ScenarioWhat it meansWhere treatment is heading
Locally advancedThe tumour has grown beyond the prostate or reached the seminal vesicles, but there are no metastasesStill with curative intent: surgery or radiotherapy, almost always with hormone therapy
Biochemical recurrenceThe PSA rises again after treatment, with no visible lesionLocate it with PSMA PET and treat the site of relapse in a targeted way
Metastatic hormone-sensitiveThere are metastases and they still respond to hormone therapyHormone therapy plus a second agent from the outset; radiotherapy to the prostate if the burden is low
Castration-resistantThe disease progresses despite testosterone being at minimal levelsFurther lines: chemotherapy, radioligands and targeted treatments guided by tumour genetics

Why this table matters more than it seems

When a patient is told his cancer is "advanced", it is natural to hear a single thing. But between the first row and the last there are years of difference and prognoses that bear no resemblance to one another: locally advanced disease is still treated to cure; castration-resistant disease is treated to prolong life with quality.

Knowing which one you are in is not a technical detail. It is what determines whether the right conversation is about cure, about prolonged control, or about both at once.

What has changed in recent years

If someone in your family went through this one or two decades ago, the picture you remember is no longer the current one. Three changes altered it fundamentally:

  • Treating with combinations from the start, rather than holding medications back until the first one stops working.
  • Better imaging, which detects the true extent far more accurately and allows treatment to be targeted.
  • Genetic testing that in some patients opens up specific treatment alternatives.

The result is not a promise of cure, but it is a real change in how long the disease stays under control and in how that time is lived.

Hormone therapy is the backbone

Prostate cancer depends on testosterone to grow. The fundamental treatment is to suppress that signal, which usually produces a rapid and clear response: a fall in PSA, relief of pain where present, and control of the lesions.

It is an effective treatment, but not a harmless one: it causes hot flushes, fatigue, loss of muscle and bone mass, and changes in sexual desire and mood. All of these effects can be anticipated and managed, and they form part of what should be reviewed at every appointment. They are not a price to be paid in silence.

Combine from the start, do not wait

This is the most important change of recent years. Treatment used to begin with hormone therapy alone, adding others once it stopped working. The evidence now supports combining from the outset: hormone therapy plus an additional targeted medication, and in selected cases chemotherapy.

Which combination applies depends on the extent of the disease, your general condition and any conditions you already have. There is no single regimen, and choosing well at the start matters more than any later adjustment.

The role of surgery and radiotherapy

Advanced disease does not rule out treatment directed at the prostate itself. In patients with low-volume metastatic disease, radiotherapy to the prostate added to systemic treatment has shown benefit. Radiotherapy is also used on specific lesions to control pain.

Surgery has a narrower but relevant role: relieving urinary obstruction, controlling bleeding or, in selected cases of locally advanced disease, forming part of treatment with curative intent.

Protecting the bones

Bone is the most frequent site of spread, and hormone therapy also weakens bone mass. These are two separate fronts addressed at the same time.

The plan therefore includes monitoring bone health, ensuring adequate calcium and vitamin D, maintaining physical activity and, when indicated, using specific medications that reduce the risk of fractures and complications. It is a part of treatment that is often neglected and that directly affects a patient's independence.

Genetic testing matters

In advanced disease it may be appropriate to test for genetic alterations in the tumour and, in certain cases, inherited ones. This has two practical consequences: some alterations open the door to specific treatments, and when they are inherited they mean your close relatives should be assessed.

Why management must be multidisciplinary

This is the central point of the whole page. Advanced prostate cancer is not solved by a single treatment or a single doctor: it requires a Urologic Oncologist to coordinate the plan and work closely with radiation oncology, medical oncology and the supportive care team.

Coordinating means deciding the order of treatments rather than improvising it; anticipating side effects rather than reacting to them; and adjusting the plan when the studies indicate it, without waiting for symptoms to appear. In practice, that continuity is what separates a controlled disease from one that advances unmonitored.

Put plainly: at this stage, who directs the treatment influences the outcome as much as which treatment is chosen.

Dr. Eduardo Amaya Fragoso performing laparoscopic surgery alongside his surgical team
Surgical team at Hospital San José. In advanced prostate cancer the outcome depends on a coordinated team — inside and outside the operating room — more than on any single treatment.

How the disease is monitored

Follow-up is what makes it possible to act in time. It rests on three elements:

  • PSA and its trend over time, which is more informative than any isolated value.
  • The testosterone level, to confirm that hormone suppression is effective.
  • Imaging studies, at the intervals appropriate to your situation.

When PSA begins to rise steadily, it does not mean the options have run out: it means the time has come to change strategy. There are several lines of treatment, and the order in which they are used is also a decision.

Quality of life is not a secondary matter

Gaining time is meaningful if that time can be lived. That is why pain control, management of the effects of hormone therapy, adapted physical activity, bone health and emotional support for you and your family are part of the treatment, not the small print.

If something is affecting your daily life, saying so in consultation is not complaining: it is clinical information that changes decisions.

Here the decisions accumulate

Why it matters who looks after you

Advanced prostate cancer has ceased to be one disease with one treatment. It is now a long sequence of decisions, each of which conditions those that follow.

  • Establishing which scenario you are inLocally advanced, biochemical recurrence, metastatic hormone-sensitive and castration-resistant are different situations with different treatments. Confusing them is the costliest error, and it happens.
  • Combining from the outsetThe evidence of recent years changed the order: adding a second agent from the start, rather than waiting for hormone therapy to fail, prolongs life. There are still patients being treated with the regimen of fifteen years ago.
  • Not abandoning local treatmentIn low-volume metastatic disease, treating the prostate with radiotherapy improves survival. It is a decision that gets lost when a case passes wholesale into systemic management without urological input.
  • Testing the genetics and coordinating the teamCertain alterations open up targeted treatments and have implications for your family. And management requires medical oncology, radiotherapy and urology talking to one another, not three parallel appointments that never meet.

What I mean is simple: in this disease almost nobody gets an operation wrong; months are lost in the decisions in between. That is where it matters who is coordinating.

A urologic oncologist is a urologist who additionally completed a postgraduate fellowship devoted solely to urological cancer. Mine was at Centro Médico Nacional Siglo XXI, accredited by UNAM. It can be verified. What exactly changes →

What to bring to your appointment

  • The full pathology report and, if available, any genetic testing report.
  • All imaging studies, on disc or with digital access — including earlier ones, so they can be compared.
  • The full sequence of your PSA values with their dates.
  • The exact list of treatments you have already received, with start and stop dates, and the reason for any change.
  • Your current medications and any conditions you have.
  • Written down on paper, the questions that matter to you. And, if you can, bring someone with you.

Related guides

If your disease is confined to the gland, the guide on localized prostate cancer describes the options with curative intent. And if it all began with an abnormal blood test, the guide on elevated PSA may help.

390+ verified patient reviews on DoctoraliaDoctoralia Excellence Certificate

Very professional. He has my complete confidence. I trust in God and in Dr. Eduardo that I will come through this.

Álvaro Verified appointment · Doctoralia · translated from Spanish

See all on Doctoralia

Dr. Eduardo Amaya Fragoso

Urologic Oncologist · Robotic Surgeon

Dr. Eduardo Amaya Fragoso

Looking for a second opinion on your treatment?

Bring your studies, your PSA history and the treatments you have already received. We will review together where the disease stands, whether the current regimen is the right one and which options remain available. A second opinion neither interrupts your treatment nor commits you to anything.

Available in person and by video consultation

Where I practise

Hospital San José, Hermosillo

Suite 301 · Module H · 3rd floor
Blvd. José María Morelos 340, Col. Bachoco, ZIP 83148
Hermosillo, Sonora

Appointments & info

662 111 0782

Hours

Monday to Friday · 8:00 AM – 8:00 PM

Saturday · 9:00 AM – 2:00 PM

Coming from another city? Travel times, length of stay and remote follow-up

Loading map…

Note

This information is for general guidance and does not replace a medical consultation. Advanced prostate cancer covers very different situations: do not make decisions about tests or treatment based on this text without discussing it with your urologist.

Message on WhatsApp Call · 662 111 0782 Book on Doctoralia Emergency